The PI focuses on cancer research at the interface between patients and in vivo and in vitro model systems in prostate carcinoma (PCa) and anaplastic large cell lymphoma (ALCL). PCa is the most frequently diagnosed cancer in men. We investigate PCa aggressiveness through hormonal (Aksoy et al. 2020), JAK/STAT (Pencik et al. 2015) and epigenetically (Limberger et al. 2022) regulated pathways. The resulting data complexity is analyzed in human patient samples and transgenic mouse models by Bioinformatics and AI, which leads to the identification of potential biomarkers for aggressive PCa entites exemplified by Oberhuber et al. 2020. Another focus is anaplastic large cell lymphoma (ALCL), a highly malignant T-cell lymphoma regulated by ALK fusions in 50% of the cases. We could show the importance of the PDGFRß for the survival of tumorcells (Laimer et al 2012) and demonstrated recently STAT5 as druggable downstream target of PDGFRß (Garces et al 2022). In addition, we are interested in the role of microplatics in tumorigenesis of coloncancer (Gruber et al 2022). This is topic of a recently funded 4 Mill € project headed by LK.